*.- Conclusions: The addition of trabectedin to PLD ( Doxorubicin ) results in superior efficacy in patients with relapsed ovarian cancer, with no added decrement to overall health status as assessed by PRO.
20 mayo 2009
ASCO Congress Proxima Semana . Pharma Mar presenta 17 Trabajos de Yondelis , Aplidin , Zalypsis e Irvalec.Varios de Fase III Ovario con Yondelis .
*.- Conclusions: The addition of trabectedin to PLD ( Doxorubicin ) results in superior efficacy in patients with relapsed ovarian cancer, with no added decrement to overall health status as assessed by PRO.